Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 10 | 2021 | 148 | 2.770 |
Why?
|
| Hypoglycemic Agents | 9 | 2021 | 83 | 1.910 |
Why?
|
| Insulin | 5 | 2012 | 109 | 1.080 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 16 | 0.800 |
Why?
|
| Metformin | 2 | 2019 | 13 | 0.790 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 5 | 0.730 |
Why?
|
| Humans | 18 | 2023 | 2493 | 0.730 |
Why?
|
| Middle Aged | 9 | 2021 | 799 | 0.660 |
Why?
|
| Adult | 8 | 2019 | 807 | 0.600 |
Why?
|
| Glycated Hemoglobin A | 5 | 2021 | 64 | 0.570 |
Why?
|
| Cholesterol | 3 | 2013 | 21 | 0.550 |
Why?
|
| Minority Groups | 2 | 2012 | 40 | 0.540 |
Why?
|
| Female | 10 | 2020 | 1733 | 0.540 |
Why?
|
| Insulin Resistance | 3 | 2012 | 44 | 0.530 |
Why?
|
| Aged | 6 | 2021 | 607 | 0.510 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 6 | 0.470 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 4 | 0.470 |
Why?
|
| Thiazolidinediones | 2 | 2011 | 22 | 0.470 |
Why?
|
| Insurance, Health | 1 | 2013 | 10 | 0.470 |
Why?
|
| Male | 9 | 2020 | 1649 | 0.470 |
Why?
|
| Poverty | 1 | 2012 | 39 | 0.450 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 33 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 64 | 0.440 |
Why?
|
| Triazoles | 1 | 2011 | 4 | 0.420 |
Why?
|
| Pyrazines | 1 | 2011 | 16 | 0.420 |
Why?
|
| Insulin, Isophane | 1 | 2010 | 3 | 0.400 |
Why?
|
| Treatment Outcome | 5 | 2023 | 119 | 0.370 |
Why?
|
| Blood Glucose | 4 | 2020 | 110 | 0.350 |
Why?
|
| Adolescent | 4 | 2013 | 305 | 0.320 |
Why?
|
| Young Adult | 3 | 2013 | 175 | 0.310 |
Why?
|
| Cholesterol, LDL | 2 | 2006 | 12 | 0.300 |
Why?
|
| Lipids | 1 | 2006 | 20 | 0.300 |
Why?
|
| Atherosclerosis | 1 | 2006 | 14 | 0.290 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 3 | 0.260 |
Why?
|
| Phytotherapy | 1 | 2004 | 4 | 0.260 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 30 | 0.240 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 40 | 0.230 |
Why?
|
| Prospective Studies | 2 | 2020 | 121 | 0.230 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 24 | 0.220 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 36 | 0.220 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 267 | 0.210 |
Why?
|
| Biomarkers | 2 | 2020 | 58 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 114 | 0.190 |
Why?
|
| Glycemic Index | 1 | 2020 | 1 | 0.190 |
Why?
|
| United States | 3 | 2017 | 324 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 31 | 0.190 |
Why?
|
| Antimalarials | 1 | 2019 | 3 | 0.180 |
Why?
|
| Treatment Failure | 1 | 2019 | 11 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2019 | 28 | 0.180 |
Why?
|
| Accelerometry | 1 | 2017 | 3 | 0.160 |
Why?
|
| Risk Factors | 2 | 2012 | 240 | 0.160 |
Why?
|
| Self Report | 1 | 2017 | 11 | 0.160 |
Why?
|
| Exercise | 1 | 2017 | 24 | 0.160 |
Why?
|
| Double-Blind Method | 3 | 2023 | 48 | 0.140 |
Why?
|
| Testosterone | 2 | 2006 | 76 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2013 | 42 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2013 | 46 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2012 | 10 | 0.120 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 6 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 21 | 0.110 |
Why?
|
| Perception | 1 | 2012 | 13 | 0.110 |
Why?
|
| Logistic Models | 1 | 2012 | 64 | 0.110 |
Why?
|
| Educational Status | 1 | 2012 | 24 | 0.110 |
Why?
|
| Los Angeles | 1 | 2012 | 210 | 0.110 |
Why?
|
| Smoking | 1 | 2012 | 49 | 0.110 |
Why?
|
| Sitagliptin Phosphate | 1 | 2011 | 3 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 1 | 0.100 |
Why?
|
| Insulin Glargine | 1 | 2010 | 2 | 0.100 |
Why?
|
| Cities | 1 | 2010 | 2 | 0.100 |
Why?
|
| Insulin, Long-Acting | 1 | 2010 | 4 | 0.100 |
Why?
|
| Weight Gain | 1 | 2010 | 10 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 11 | 0.100 |
Why?
|
| Nicotine | 1 | 2012 | 89 | 0.100 |
Why?
|
| Apolipoproteins B | 2 | 2006 | 5 | 0.090 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 9 | 0.090 |
Why?
|
| African Americans | 1 | 2012 | 272 | 0.090 |
Why?
|
| Triglycerides | 2 | 2006 | 36 | 0.090 |
Why?
|
| Demography | 1 | 2006 | 13 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2006 | 35 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 3 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 10 | 0.070 |
Why?
|
| Weight Loss | 1 | 2006 | 17 | 0.070 |
Why?
|
| Cytokines | 1 | 2006 | 47 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2006 | 210 | 0.070 |
Why?
|
| HIV Infections | 1 | 2006 | 91 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2004 | 18 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 36 | 0.060 |
Why?
|
| Chromans | 1 | 2004 | 1 | 0.060 |
Why?
|
| Annexin A2 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 8 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2004 | 15 | 0.060 |
Why?
|
| Quality of Life | 1 | 2004 | 60 | 0.060 |
Why?
|
| Adipocytes | 1 | 2004 | 26 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2023 | 1 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 5 | 0.050 |
Why?
|
| Glucagon-Like Peptides | 1 | 2021 | 1 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 1 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 6 | 0.050 |
Why?
|
| Selenium | 1 | 2000 | 2 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2000 | 10 | 0.050 |
Why?
|
| Fructosamine | 1 | 2020 | 1 | 0.050 |
Why?
|
| Glycation End Products, Advanced | 1 | 2020 | 2 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2020 | 11 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 16 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2000 | 13 | 0.050 |
Why?
|
| Prognosis | 1 | 2020 | 47 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 95 | 0.050 |
Why?
|
| Morbidity | 1 | 2017 | 7 | 0.040 |
Why?
|
| Animals | 2 | 2012 | 1238 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Biological Transport | 2 | 2004 | 13 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2012 | 13 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2012 | 35 | 0.030 |
Why?
|
| Thrombosis | 1 | 2006 | 3 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2006 | 4 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2006 | 10 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 27 | 0.020 |
Why?
|
| Comorbidity | 1 | 2006 | 54 | 0.020 |
Why?
|
| California | 1 | 2006 | 93 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 44 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 5 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 5 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 6 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2004 | 16 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2004 | 24 | 0.020 |
Why?
|
| Glucose | 1 | 2004 | 39 | 0.020 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 2 | 0.010 |
Why?
|
| Triptorelin Pamoate | 1 | 2002 | 2 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2002 | 2 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 508 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 4 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 17 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 50 | 0.010 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 2 | 0.010 |
Why?
|
| Cell Size | 1 | 2000 | 3 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 4 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 7 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 4 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 39 | 0.010 |
Why?
|
| Amino Acids | 1 | 2000 | 16 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2000 | 31 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 28 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 67 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 25 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 45 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 37 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 162 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 167 | 0.010 |
Why?
|